Lung cancer stem cells: Tumor biology and clinical implications

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 3, 2012, Pages 217-222

  Nurwidya, Fariz ^a   Murakami, Akiko ^a   Takahashi, Fumiyuki ^a   Takahashi, Kazuhisa ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical implication; Lung cancer stem cells; Tumor biology

Indexed keywords

ALDEHYDE DEHYDROGENASE; BREAST CANCER RESISTANCE PROTEIN; CYTOKERATIN 14; FIBROBLAST GROWTH FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TENSIN; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR SNAIL;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CELL REGENERATION; COLONY FORMATION; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPE; LONG TERM SURVIVAL; LONGEVITY; LUNG CANCER; MESENCHYMAL STEM CELL; NONHUMAN; OVERALL SURVIVAL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SURVIVAL;

ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865439719     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01550.x     Document Type: Review

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Rengan R, Maity AM, Stevenson JP, Hahn SM. New strategies in non-small cell lung cancer: improving outcomes in chemoradiotherapy for locally advanced disease. Clin Cancer Res 2011; 17: 4192-9.
3. Perona R, López-Ayllón BD, Carpeño JC, Belda-Iniesta C. A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. Clin Transl Oncol 2011; 13: 289-93.
4. Mimeault M, Batra SK. Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 2006; 24: 2319-45.
5. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58: 267-84.
6. Biswas A, Hutchins R. Embryonic stem cells. Stem Cells Dev 2007; 16: 213-22.
7. Ginis I, Luo Y, Miura T etal. Differences between human and mouse embryonic stem cells. Dev Biol 2004; 269: 360-80.
8. Bibikova M, Chudin E, Wu B etal. Human embryonic stem cells have a unique epigenetic signature. Genome Res 2006; 16: 1075-83.
9. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007; 25: 2739-49.
10. Bender-Kim CF, Jackson EL, Woolfenden AE etal. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-35.
11. Giangreco A, Arwert EN, Rosewell IR, Snyder J, Watt FM, Stripp BR. Stem cells are dispensable for lung homeostasis but restore airways after injury. Proc Natl Acad Sci U S A 2009; 106: 9286-91.
12. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL. Cancer stem cells - perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
13. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells - old concepts, new insights. Cell Death Differ 2008; 15: 947-58.
14. Hirschmann-Jax C, Foster AE, Wulf GG etal. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A 2004; 101: 14228-33.
15. Ho M, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-33.
16. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317: 337.
17. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-84.
18. Giangreco A, Groot KR, Janes SM. Lung cancer and lung stem cells: strange bedfellows? Am J Respir Crit Care Med 2007; 175: 547-53.
19. Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, Hegab AE. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res 2010; 70: 6639-48.
20. Scaffidi P, Misteli T. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol 2011; 13: 1051-61.
21. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-73.
22. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2012; 29: 4741-51.
23. Mani SA, Guo W, Liao MJ etal. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
24. Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007; 17: 3-14.
25. Saini V, Shoemaker RH. Potential for therapeutic targeting of tumor stem cells. Cancer Sci 2010; 101: 16-21.
26. Jiang F, Qiu Q, Khanna A etal. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009; 7: 330-8.
27. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell 2007; 1: 555-67.
28. Li C, Heidt DG, Dalerba P etal. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
29. Bertolini G, Roza L, Perego P etal. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009; 106: 16281-6.
30. Eramo A, Lotti F, Sette G etal. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-14.
31. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer 2010; 126: 950-8.
32. Cui F, Wang J, Chen D, Chen YJ. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol Rep 2011; 25: 701-8.
33. Peacock CD, Watkins DN. Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 2008; 26: 2883-9.
34. Katayama K, Shibata K, Mitsuhashi J, Noguchi K, Sugimoto Y. Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling. Anticancer Res 2009; 29: 1059-66.
35. Singh A, Wu H, Zhang P, Happel C, Ma J, Biswal S. Expression of ABCG2 (BCRP), a marker of stem cells, is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther 2010; 9: 2365-76.
36. An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 2009; 5: 1529-42.
37. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol 2008; 26: 2795-9.
38. Gorelik E, Lokshin A, Levina V. Lung cancer stem cells as a target for therapy. Anticancer Agents Med Chem 2010; 10: 164-71.
39. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011; 17: 313-19.
40. Kratz JR, Yagui-Beltrán A, Jablons DM. Cancer stem cells in lung tumorigenesis. Ann Thorac Surg 2010; 89: 2090-5.
41. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007; 23: 675-99.
42. Lennartsson J, Rönnstrand L. The stem cell factor receptor/c-kit as a drug target in cancer. Curr Cancer Drug Targets 2006; 6: 561-71.
43. Levina V, Marrangoni A, Wang T, Parikh S, Su Y, Herberman R. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 2010; 70: 338-46.
44. Fan X, Matsui W, Khaki L etal. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66: 7445-52.
45. Grudzien P, Lo S, Albain KS etal. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 2010; 30: 3853-67.
46. Eliasz S, Liang S, Chen Y etal. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene 2010; 29: 2488-98.
47. Wang Z, Li Y, Banerjee S, Sarkar FH. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res 2008; 28: 3621-30.
48. Pannuti A, Foreman K, Rizzo P etal. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010; 16: 3141-52.
49. Sung JM, Cho HJ, Yi H etal. Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 2008; 371: 163-7.
50. Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, Powles T. A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. Mol Cancer Ther 2010; 9: 3322-9.
51. Mi YJ, Liang YJ, Huang HB etal. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res 2010; 70: 7981-91.
52. Kitamura H, Okudela K, Yazawa T, Sato H, Shimoyamada H. Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer 2009; 66: 275-81.